Members are advised about the current worldwide shortage of Vyvanse ® 30mg, 50mg and 60mg (lisdexamfetamine dimesilate) due to manufacturing issues. 

The TGA has approved an overseas-registered alternative to Vyvanse 30 mg under section 19A of the Therapeutic Goods Act 1989. You can find details about this medicine on the Section 19A approvals database.

The details of these shortages and how long they may last can change. Check the Medicine Shortage Reports Database (search for ‘Vyvanse’) for the most up-to-date details. Members will be advised as further details regarding the shortages are made available by the TGA.